Also known as: OpenAI
OpenAI is an AI research and deployment company whose mission is to ensure that AGI benefits all of humanity. It operates through a nonprofit foundation and a for-profit public benefit corporation structure.
Benchmark studies show general-purpose LLMs like GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools and physicians on diagnostic reasoning tasks. Domain-adapted LLMs also beat larger generic models on clinical research tasks, while agentic systems show only modest gains. Regulatory clearance pathways have not yet addressed comparative performance.
More than 80% of U.S. physicians use AI in their work. AI is revealing new cardiac biomarkers and speeding drug discovery, with the healthcare AI market projected to reach $505.6 billion by 2033—but studies warn of bias and eroding critical thinking.
Sheba Medical Center becomes first hospital outside the US to adopt OpenAI's healthcare AI models. Jerusalem launches FourWard medical innovation hub, and international health leaders visit Israeli labs to study medical innovation.
Semiconductor stocks surged as Intel, AMD, and POET hit fresh highs on AI infrastructure demand, while SemiLEDS jumped 17.96% after a Q3 turnaround. Intel posted stronger-than-expected Q1 earnings and upbeat Q2 guidance.
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
Bristol Myers Squibb will deploy Anthropic’s Claude across global operations, putting the AI platform in the hands of more than 30,000 employees. BMS plans to use it in R&D, clinical development, manufacturing and commercial work.
Thrive Capital has raised more than $10 billion in its largest fund ever. The fundraising was heavily oversubscribed and the cash influx was double the size of its last fund.
Generative AI processed complex medical datasets faster than traditional teams in a preterm birth study, while the healthcare market for the technology reached US$2.92 billion in 2024. The market is projected to grow to US$30.68 billion by 2033 as adoption expands in clinical workflows, imaging, drug discovery and precision medicine.
Recent studies reveal AI chatbots face significant challenges in medical applications, with one study showing ChatGPT Health under-triaged 51.6% of emergency cases. Cancer patients using an AI chatbot experienced 22% withdrawal rates due to usability issues, while medical researchers show cautious adoption with 40.3% reporting AI use in research.
OpenAI Foundation has pledged $1 billion in grants over the next year to support life science and health research while addressing AI's impacts on jobs and mental health. The nonprofit will recruit a new executive director to oversee grantmaking as part of its revitalized philanthropic mission.
